|
市場調查報告書
美國及歐盟肥胖治療藥市場
Obesity Drug Markets in the US and EU: Analysis of product pipelines and the competitive environmen
|
美國及歐盟肥胖治療藥市場 是由出版商Business Insights在2008年07月所出版的。
這份英文市場調查報告書包含148 pages 價格從美金3835起跳。
肥胖已成為主要先進國家的一大問題，2008年美國人有32%、歐盟有17%的肥胖人口。
本報告書內容包括：肥胖治療的最新動向、目前的上市產品動向及醫療實驗中的藥物、未來銷售預測等。內容綱要摘記如下：
實施概要
第1章 逐漸擴大的肥胖問題
- 摘要
- 威脅生命的症狀
- 肥胖水準
- 肥胖問題擴大
- 對社會及經濟的影響
- 醫療概要
- 肥胖是造成代謝症候群的要素
- 結論
第2章 目前的肥胖管理方針
- 摘要
- 背景
- 減肥及運動計畫
- OTC減重維他命
- 藥品
- 外科方法
- 選擇比較
- 潛在需求
- 結論
第3章 肥胖治療藥品
第4章 肥胖治療藥產品線
- 摘要
- 介紹
- 上市前醫療實驗
- 第1階段
- 第2階段
- 第3階段
- 主要治療藥候選名單
- 中止的治療藥
- 結論
第5章 市場預測
圖表
Abstract
The rising prevalence of obesity is a growing problem in developed countries,
with 32% of Americans and 17% of EU residents considered obese in 2008. The
condition is associated with a range of severe co-morbidities, the most
significant of which include asthma, cardiovascular disease, cancer, diabetes,
hypertension and kidney disease. Obesity-related treatments cost healthcare
payors billions of dollars each year, and the market for medications is
steadily expanding as incidence of obesity continues to increase. Stringent
regulations have restricted the amount of medications currently available,
however many currently marketed products are failing to meet consumer needs.
' Obesity Drug Markets in the US and EU: Analysis of product pipelines and
competitive environment' is a new report published by Business Insights that
explores the dynamics and drivers of the market for current and emerging
obesity treatments. This report evaluates the performances and attributes of
currently marketed products and highlights the most effective strategies for
securing future success in this therapeutic area. The potential of leading
obesity drug candidates is assessed and over 100 compounds are identified
across pre-clinical, Phase I, Phase II and Phase III development. Forecasts of
future sales are also provided, based upon trends in obesity drug usage,
projected prevalence rates and the approval potential of emerging products.
Explore the latest trends and innovations in obesity treatments, assess the
performances of currently marketed medications and evaluate the potential of
leading pipeline candidates with this report.
Table of Contents
Executive Summary
- The large and growing obesity problem
- Current approaches to obesity management
- Pharmaceutical options for the treatment of obesity
- The obesity drug pipeline
- Market forecasts
Chapter 1 The large and growing obesity problem
- Summary
- A potentially life threatening medical condition
- Levels of obesity
- Overweight
- Obesity
- Morbid obesity
- Super obesity
- Co-morbidities and mortality
- Arthritis
- Asthma
- Cancer
- Cardiovascular disease and hypertension
- Dementia
- Depression
- Diabetes
- Kidney disease
- Rising prevalence of obesity
- Trends by sub-population
- Obesity in children and adolescents
- Heavy social and economic impact
- Cost burden
- Social effects
- Societal and other effects
- Medical overview of obesity
- Pathogenesis of obesity
- Physiological factors
- Genetic factors
- Environmental factors
- Lifestyle factors
- Psychological factors
- Societal trends
- Obesity as a component of metabolic syndrome
- Conclusion
Chapter 2 Current approaches to obesity management
- Summary
- Background
- Diet and exercise programs
- Dieting
- Types of programs
- Patient volumes
- Exercise
- Types of programs
- Patient volumes
- OTC weight loss supplements
- Types of products
- Patient volumes
- Pharmaceutical options
- Types of medications
- Patient volumes
- Surgical intervention
- Types of procedures
- Patient volumes
- Comparison of options
- Safety
- Efficacy
- Cost
- Unmet needs
- Conclusion
Chapter 3 Pharmaceutical options for treatment of obesity
- Summary
- Leading prescription medications
- Meridia
- Xenical
- Acomplia
- Others
- OTC medicines
- Alli
- Comparison of pharmaceutical options
- Safety
- Efficacy
- Cost
- Conclusion
Chapter 4 The obesity drug pipeline
- Summary
- Introduction
- Pre-clinical testing
- Phase I testing
- Phase II testing
- Phase III testing
- Leading obesity drug candidates
- Lorcaserin hydrochloride
- Lepislim
- Taranabant
- Contrave
- CP-945,598
- Qnexa
- Discontinued obesity drug candidates
- Conclusion
Chapter 5 Market forecasts
- Summary
- Introduction
- Current sales levels
- United States
- Europe
- Five year forecasts
- United States
- Europe
- Conclusion
- Index
List of Figures
- Figure 1.1: Rates of obesity and overweight in the US, 1980-2006
- Figure 1.2: Rates of obesity and overweight in Europe, 1980-2006
- Figure 2.3: Comparison of safety, efficacy and cost of obesity management
approaches
- Figure 3.4: Comparison of safety, efficacy and cost of pharmaceutical
options for obesity management
- Figure 4.5: Comparison of leading obesity drug candidates, 2008
- Figure 5.6: Obesity medication sales in the US and EU, 2006 and 2007
- Figure 5.7: Obesity medication sales by region, 2007
- Figure 5.8: Obesity medication sales in the US and EU, 2008-2013
- Figure 5.9: Total obesity medication sales by region, 2008-2013
List of Tables
- Table 1.1: Proportion of cancers related to obesity
- Table 1.2: Prevalence of adult overweight and obesity by country, 2003
- Table 2.3: US and EU patient caseloads for leading obesity management
approaches, 2007-12 (millions of persons)
- Table 2.4: Safety risks associated with obesity management approaches
- Table 2.5: Comparative efficacy of obesity management approaches
- Table 3.6: Safety risks associated with leading obesity medications
- Table 3.7: Safety risks associated with leading obesity management
approaches
- Table 3.8: US cost comparison for leading obesity medications, 2008
- Table 4.9: Pharmaceutical pipeline for obesity medications
- Table 4.10: Discontinuations of obesity drug programs
- Table 5.11: US sales of obesity medications, 2006 and 2007
- Table 5.12: European sales of obesity medications, 2006 and 2007
- Table 5.13: US sales of obesity medications in $m, 2008-2012
- Table 5.14: European sales of obesity medications in $m, 2008-2012
|
